Tucatinib, a recently FDA-approved drug has shown efficacy in metastatic HER2+ breast cancer patients with brain metastases16, will be studied in the post-neoadjuvant setting combined with T-DM1 in the COMPASS-RD (NCT04457596) trial. Here, ERBB2 is linked to breast cancer.